The Flow Cytometry Core Facility (FCCP) provides state-of-the-art flow cytometry services to researchers at the Cancer Center. Extensive user support is provided, consisting of daily instrument startup, maintenance and quality control;easy and reliable online scheduling systems;extensive training options;a site license for FlowJo analysis software;one-on-one consultations between individual researchers and Core Facility staff. These services include Operator-Assisted analysis on FACSCalibur and CyAn, Operator-Assisted cell sorting on two Aria and two MoFlo cell sorters, as well as User-Operated analysis on FACSCalibur, LSR II and Fortessa and User-Operated cell sorting on two Aria cell sorters. The combination of equipment and user support offers researchers opportunity to integrate flow cytometric analysis and cell sorting into their research projects. FCCP provides easy access to purified cell populations and to analysis of cellular subsets and processes, essential elements of many modern cell biology research projects. The presence of FCCP therefore plays an important role in the Center's capability to increase our knowledge of the processes that give rise to cancer, and to improve cancer diagnosis and therapy. The services and collaborative work provided by the FCCF has supported the research of 111 investigators in the past year. During the past grant period the work of the Core has contributed to 450 publications of researchers from 8 research programs. For example, the Flow Core was essential in helping the Rudensky lab demonstrate that regulatory T(Treg) cells integrate environmental cues that suppress particular types of Inflammation. These studies showed that Treg cell-mediated suppression of Th17-driven pathology is facilitated by activation of STAT3 downstream of interleukin 10-R (IL-1 OR) engagement of interleukin 10 (IL-10). This study demonstrated that IL-10 endows Treg cells with the ability to suppress pathogenic Thi7 cell responses. For these studies the Core provided expert flow analysis of STAT3 staining and cell sorting of Fox3-YFPT+ and Fox3-TFP- cells.

Public Health Relevance

The FCCF provides essential services and instrumentation that enable Center investigators to simultaneously analyze multiple characteristics on large numbers of cells and to Isolate highly purified populations of cells that have specific features.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8933486
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$362,498
Indirect Cost
$158,504
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kavaler, Joshua; Duan, Hong; Aradhya, Rajaguru et al. (2018) miRNA suppression of a Notch repressor directs non-neuronal fate in Drosophila mechanosensory organs. J Cell Biol 217:571-583
Bosse, Tjalling; Nout, Remi A; McAlpine, Jessica N et al. (2018) Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol 42:561-568
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Scordo, Michael; Morjaria, Sejal M; Littmann, Eric R et al. (2018) Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1914-1919
Byron, Sara A; Tran, Nhan L; Halperin, Rebecca F et al. (2018) Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res 24:295-305
Zarnegar, Sara; Durham, Benjamin H; Khattar, Pallavi et al. (2018) Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 65:
Francis, Jasmine H; Slakter, Jason S; Abramson, David H et al. (2018) Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab. Am J Ophthalmol Case Rep 11:49-51
Lee, Stanley Chun-Wei; North, Khrystyna; Kim, Eunhee et al. (2018) Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell 34:225-241.e8
Motzer, Robert J; Escudier, Bernard; Powles, Thomas et al. (2018) Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 118:1176-1178
Giancipoli, Romina Grazia; Monti, Serena; Basturk, Olca et al. (2018) Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography: A CARE case report. Medicine (Baltimore) 97:e12795

Showing the most recent 10 out of 8799 publications